Rubicon Advisors’s Eli Lilly LLY Stock Holding History

Rubicon Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$586K	Sell	489 -10	-2%	-$10.2K	0.43%	51
2026 Q1	$459K	Hold	499	–	–	0.4%	46
2025 Q4	$536K	Buy	+499	New	+$477K	0.5%	35

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rubicon Advisors's LLY Position: Q2 2026 in Review

Rubicon Advisors reduced its Eli Lilly (LLY) stake by 2% in Q2 2026, selling an estimated $10.2K and leaving 489 shares worth $586K. The position accounts for 0.43% of the portfolio, ranked #51.

Rubicon Advisors first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,594 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Rubicon Advisors held 489 shares of Eli Lilly worth $586K as of Q2 2026.
Rubicon Advisors sold 10 Eli Lilly shares in Q2 2026, an estimated $10.2K.
Eli Lilly made up 0.43% of Rubicon Advisors's portfolio in Q2 2026, its #51 holding.
Rubicon Advisors first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
4,594 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Rubicon Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.